Content Type: Article

  • Anti-Money Laundering Update: Treasury to Re-Propose Long Anticipated AML Program Rules Aimed at Hedge Funds, PE Funds and Certain Investment Advisers

    Anti-Money Laundering Update: Treasury to Re-Propose Long Anticipated AML Program Rules Aimed at Hedge Funds, PE Funds and Certain Investment Advisers

    ARTICLE / CLIENT ALERT

    Anti-Money Laundering Update: Treasury to Re-Propose Long Anticipated AML Program Rules Aimed at Hedge Funds, PE Funds and Certain Investment Advisers

    December 22, 2023

    Read time: 6 min

    Key takeaways
    Overview

    On Dec. 11, 2023, the US Department of the Treasury (“Treasury”) issued a statement[1] that it plans to release an updated notice of proposed rulemaking (“NPRM”) prescribing anti-money laundering/counter terrorist financing (“AML/CFT”) obligations for certain investment advisers in the first quarter of 2024.

    Treasury’s statement highlights that investment advisers are not presently subject to consistent or comprehensive AML/CFT obligations in the United States and expresses its concern that this gap in regulation creates “the risk that corrupt officials and other illicit actors may invest ill-gotten gains in the US financial system through hedge funds, private equity firms, and other investment services.” 

    The issuance of this updated NPRM has long been anticipated, given that the Financial Crimes Enforcement Network (“FinCEN”), a bureau of Treasury responsible for administering the Bank Secrecy Act, has previously proposed AML regulations for investment advisers — most recently in 2015 — but has never finalized them.[2] Since 2015, Treasury and FinCEN have made various statements in publications and speeches noting their concern about the issues this absence of regulation creates.[3] For example, the US Strategy on Countering Corruption, a publication issued by Treasury in December 2021,[4] noted, among other things, that “the lack of regulatory oversight of [investment advisers] means that it [is] possible for money launderers to evade scrutiny more effectively by operating through investment advisers rather than through broker-dealers or banks directly.”[5] In the 2022 release of the National Money Laundering Risk Assessment, Treasury provided a comprehensive summary of the attributes of the investment advisor industry that it identified as creating vulnerabilities that illicit actors may be able to exploit, including the industry’s lack of AML/CFT regulatory requirements.[6] FinCEN ‘s then-Acting Director Himamauli Das also gave a statement in 2022 before the House Committee on Financial Services where he noted that “the lack of a comprehensive AML/CFT regulatory framework for investment advisers may create vulnerabilities that illicit actors may be able to exploit.”[7] More recently, in 2023, Treasury’s Under Secretary for Terrorism and Finance Brian Nelson and FinCEN Director Andrea Gacki hinted that Treasury was working to address risks presented by the investment adviser sector.[8]

    If the updated NPRM is similar to FinCEN’s 2015 NPRM, the updated NPRM would solicit public comments on whether SEC-registered investment advisers of private funds should be included in the general definition of “financial institution” in the Bank Secrecy Act implementing regulations and, as such, required to establish an AML program, file currency transaction reports and suspicious activity reports with FinCEN, and maintain certain transaction records. The updated NPRM may also address whether investment advisers will be required to develop investor identity verification and due diligence procedures.

    Treasury’s statement was part of a press release about Treasury’s broader initiatives to address the illicit finance and national security threats posed by corruption — including prioritizing efforts to implement FinCEN’s Beneficial Ownership Reporting Rule, which will become effective on Jan. 1, 2024,[9] and issuing a NPRM in the first quarter of 2024 to solicit public comments on AML/CFT requirements for the residential real estate sector.

    Investment advisers should prepare to evaluate their AML policies and procedures next year in light of the proposed regulatory changes.

    Authored by Betty Santangelo, Melissa G.R. Goldstein, Kyle B. Hendrix and Jonice Q. Jackson.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Treasury, FACT SHEET: US Department of the Treasury Actions to Prevent and Disrupt Corruption (Dec. 11, 2023), available here.

    [2] FinCEN, Anti-Money Laundering Program and Suspicious Activity Report Filing Requirements for Registered Investment Advisers, 80 Fed. Reg. 52680 (Sept. 1, 2015), available here. For more information regarding the 2015 proposed rule, please see our prior Alert, “New Anti-Money Laundering Rules for Registered Investment Advisers Proposed by FinCEN,” available here.

    [3] Certain provisions of the Bank Secrecy Act (31 U.S.C. 5311 et seq.) already apply to investment advisers, but investment advisers are not yet subject to regulations requiring the implementation of an AML program.

    [4] The White House, United States Strategy on Countering Corruption (Dec. 2021), available here.

    [5] Id. at 22.

    [6] US Department of the Treasury, “National Money Laundering Risk Assessment” (Feb. 2022), at 63-66, available here.

    [7] Himamauli Das, “Statement by Himamauli Das Acting Director Financial Crimes Enforcement Network United States Department of the Treasury before the Committee on Financial Services US House of Representatives” (April 28, 2022), available here.

    [8] See Brian Nelson, “Remarks by Under Secretary for Terrorism and Financial Intelligence Brian Nelson at Deloitte’s 15th Annual Anti-Money Laundering Conference” (Oct. 17, 2023), available here (“We are also turning our sights to investment advisers, a set of professionals in a $120 trillion sector that are generally not subject to comprehensive AML/CFT obligations. Investment advisers have facilitated the movement of illicit proceeds tied to a range of predicate crimes — including foreign corruption, fraud, tax and sanctions evasion, and can also be exploited by our adversaries to invest in sensitive US technologies. We are conducting risk assessments on this sector and are considering possible policy options.”); see also Andrea Gacki, “Prepared Remarks of FinCEN Director Andrea Gacki During ACAMS: The Assembly (delivered virtually)” (Oct. 3, 2023), available here (“FinCEN, along with our Treasury colleagues, has been examining the money laundering risks and vulnerabilities with certain “gatekeeper” industries such as real estate and investment advisers, and identifying how best to address those risks.”)

    [9] For additional information on the Corporate Transparency Act, please see our prior client Alerts: (1) “FinCEN Issues Final Rule Requiring Reporting of Beneficial Ownership Information,” available here; (2) “The Corporate Transparency Act: Key Considerations for Compliance With the Beneficial Ownership Reporting Rule,” available here and (3) “The Corporate Transparency Act: The Private Funds Guide to Compliance With the Beneficial Ownership Reporting Rule,” available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2023 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    Jonice Q. Jackson

    Associate

    Washington, DC

    More insights

  • New FTC, DOJ Merger Guidelines Create Challenges and Opportunities

    New FTC, DOJ Merger Guidelines Create Challenges and Opportunities

    ARTICLE / CLIENT ALERT

    New FTC, DOJ Merger Guidelines Create Challenges and Opportunities

    December 21, 2023

    Read time: 11 min

    Key takeaways
    Overview

    The US Federal Trade Commission (FTC) and US Department of Justice Antitrust Division (DOJ) issued their updated Merger Guidelines on December 18, 2023.

    These guidelines represent a significantly more enforcement-oriented approach than the prior guidelines, and they largely follow the contours of draft guidelines released in July 2023. Companies should be aware of the Merger Guidelines and their implications as they formulate strategies for assessing potential merger and acquisition options. However, the guidelines are not the law, and the FTC and DOJ (Agencies) have experienced many losses—or have accepted settlements allowing transactions to proceed—when pursuing some of the more aggressive theories discussed in these new Merger Guidelines. So, despite challenges posed by the guidelines’ more enforcement-oriented approach, many opportunities and strategies remain for successful regulatory clearance.

    In depth

    The prior Merger Guidelines’ unifying theme was that mergers should not be allowed to raise price or reduce output, quality or innovation. The various analyses in the document informed the assessment of that underlying issue.

    The 2023 Merger Guidelines replace that theme with a long list of potential enforcement theories, including several from the prior guidelines (such as findings that mergers between close competitors or mergers that significantly raise concentration can be problematic).

    In other areas, the Merger Guidelines introduce concepts not addressed in the prior version, such as more expansive theories of potential entry, mergers entrenching a dominant position, and merger impacts on labor markets. The net result of the new guidelines is that the Agencies have codified what has been apparent to practitioners in recent years: that parties and counsel need to be prepared to defend a transaction on a range of horizontal, vertical and potential competition theories. Equally important, since the Agencies’ theories go beyond current case law, counsel needs to be prepared, and have time, to litigate merger challenges. As noted below, that has been the route many companies have followed recently to secure approval of their transactions.

    DRAFT VERSUS FINAL GUIDELINES

    After publishing a draft of these guidelines in July 2023, the Agencies assessed public comments and then released the final Merger Guidelines. Our assessment of the earlier draft is available in this On the Subject.

    The final Merger Guidelines are largely consistent with the earlier draft, but they include some changes that, on the surface, make the guidelines appear more flexible than the draft. For example, the draft guidelines laid out many different situations in which the agency would “presume” a transaction violates the law, and those statements went well beyond the law. In the final Merger Guidelines, the Agencies back off their position that various structural factors give rise to a “presumption” of illegality. However, they retain the same concepts by describing how those factors will cause the Agencies to “infer” that a transaction is anticompetitive.

    While the final Merger Guidelines tone down language setting out presumptions that go beyond the cases, the concepts remain firmly part of the document.

    MAJOR THEMES IN THE MERGER GUIDELINES

    Below are some of the key themes and takeaways in the new Merger Guidelines, as well as non-exhaustive thoughts on some actions companies can consider to best position themselves to succeed in this environment (by creating rebuttal evidence that can overcome the prima facie case the Agencies will look to establish using these themes). Experienced counsel can help companies in assessing these facts and developing evidence to rebut, and resist, a governmental challenge.

    Mergers raise a presumption of illegality at lower market shares and concentration levels. In light of this guidance, contesting relevant market definition in which to measure shares will be even more important than in the past. Parties must understand their documents and the arguments they will support, or foreclose, to inform this analysis. In addition, it may become more important to engage economists early to assist in econometric work that can help define appropriate and defensible relevant markets. This will become even more pronounced if the proposed new Hart-Scott-Rodino filing rules come into place later this year. Those draft rules, also released over the summer, will require parties to take affirmative positions on issues such as relevant markets, shares and concentration with their initial filings.

    Mergers between close competitors are particularly suspect, even if they compete in a broader market. This theme incorporates and expands upon the concepts of “unilateral effects” arising from mergers of close competitors that have been part of the merger reviews for many years. It has been, and remains, important for companies to understand whether they are particularly close rivals that are differentiated from other firms. Understanding how the businesses look at each other in their ordinary course documents is important to evaluating the likelihood of successfully navigating the review process. It also is important for counsel to have access to the types of documents that will be disclosed in a merger review to provide a meaningful risk assessment, and to help develop clearance strategies early in the deal process.

    Coordinated effects analysis is more important in the Agencies’ reviews. The coordinated effects analysis assesses whether the elimination of one competitor through a merger will make it more likely that the remaining firms will be able to coordinate their pricing and other actions. This does not require an illegal agreement, but the theory is that with fewer firms there is a greater likelihood that competitors will be able to observe each other’s actions and pull their punches. The Merger Guidelines show that the Agencies are very skeptical that parties will be able to overcome the inference of increased coordination in a concentrated market, but it is important that merging parties attempt to do so. This can entail understanding the types of normal interactions and competitive information available to parties. For example, the Agencies are very focused on price increase announcements and similar activities through which competitors can learn of their rivals’ actions, even if there is a legitimate purpose for the disclosures. Given the increased importance of these coordinated effects theories, counsel need to understand industry dynamics to help develop effective rebuttals.

    Mergers involving a potential entrant into a market face greater scrutiny. Potential entry is not a new theory, and it was part of the prior guidelines. Potential entry involves situations in which one of the merging parties may be positioned to enter, or may be perceived by the current competitors as positioned to enter, a market in competition with the company with which it is merging. The new Merger Guidelines take an expansive approach to potential entry and the competitive benefits such entry would deliver to customers. In light of the expansive theories of harm based on potential entry, companies should assess what their documents and facts will demonstrate in terms of whether one of the merging parties is capable of entering, has considered entering or has planned to enter, or is perceived by others (including the merger partner) as being well positioned to enter a market. Companies should demonstrate, if accurate, that they lack key resources for entering or have affirmatively rejected entering for business reasons unrelated to the proposed acquisition.

    Vertical and other non-horizontal transactions are treated as far more problematic than they were in the short-lived 2020 Vertical Merger Guidelines issued by the Trump administration. In one respect, the Merger Guidelines pull back from the earlier draft, because they do not include a presumption that a vertical merger in which one party has a 50% share of a vertically related input product is anticompetitive. That change resolves a clear disconnect between the draft guidelines and the case law, because multiple courts have addressed the legal standard for vertical challenges in recent years, and they have rejected any concept of a market share-based presumption in a vertical transaction. Nevertheless, the Agencies can bring vertical challenges under a full rule of reason framework, and the Merger Guidelines make clear that having a 50% or greater share for a vertical transaction will be viewed with suspicion. Parties pursuing vertical transactions should evaluate and be prepared to demonstrate there is no ability to foreclose or degrade access to the input product, and there is no incentive to withhold or degrade access. Many different factors come in to play, such as: the existence of strong alternative supply options for the vertically related input product; the merging party’s share of the input product (i.e., shares lower than 50% would support an argument that the combined company would not have an ability or incentive to withhold or degrade access); and various commercial factors that may provide an incentive to supply the product or service despite the vertical integration. Also, in some cases, courts have viewed open offers or commitments of continued supply as important facts undercutting a governmental challenge to deals.

    Transactions are more likely to be flagged as problematic if the industry has experienced, or is undergoing, consolidation. The Merger Guidelines stress how prior consolidation in an industry can be an aggravating factor in their merger review. Likewise, when multiple mergers are in process in an industry, the Agencies will be more likely to find a transaction to be anticompetitive. It is important for companies and counsel to consider and evaluate previous industry consolidation. If there have been prior transactions, it will likely be important to assess—and be ready to advocate about—whether and how competition changed following those deals. Key factors include the occurrence and magnitude of post-transaction price increases, changes in profit margins, or other indicia of competition such as innovation or levels of output (both for the merging parties and for other industry participants).

    Private equity and roll-up transactions are assessed by the concentration and consolidation resulting from a series of transactions rather than the incremental change created by the most recent addition to a platform. The FTC, DOJ and others in government have made clear their concerns with the private equity business model, including the concept of multiple roll-up transactions in an industry. When evaluating a current merger, the Agencies will want to understand how market shares and concentration have changed over time and whether prior acquisitions have contributed to those changes. Under this rubric, a current acquisition that has a relatively minor impact on shares and concentration could be viewed differently when viewed as the latest step among multiple transactions, each of which has incrementally changed the market shares and concentration from the baseline. Companies involved in a series of transactions will want to evaluate not just the current deal, but the competitive impacts of a preceding series of transactions. Transaction documents that highlight past or anticipated industry consolidation are likely to catch the regulators’ attention and should be avoided where practicable.

    Tech industries are a major focus. The Agencies have multiple guidelines they can use to attack tech industry transactions, including guidelines focused on multi-sided platforms, lowering the standard for challenging deals based on potential competition, and reintroducing 1960s-era theories around entrenchment of a dominant position. Changes from the draft to the final Merger Guidelines include the addition of new concepts that appear to be focused on technology companies, such as describing competitive issues that arise from factors such as interconnectivity of products that are common in technology platforms. Companies considering transactions in the tech space will need to take a holistic approach when evaluating the risks and preparing defenses.

    LITIGATION CAN BE A VIABLE PATH TO DEAL CLEARANCE

    The new Merger Guidelines reflect the current anti-merger stance at the Agencies, but they are not the law and should not deter companies from considering lawful transactions, even if disfavored by the current administration. The Merger Guidelines lay out the Agencies’ enforcement framework, but both DOJ and FTC are resource-constrained and so need to prioritize which transactions to investigate and challenge. In the past two years, the courts have rejected some of the Agencies’ more aggressive approaches or theories involving potential competition (Meta/Within), vertical foreclosure (United Health/Change Health; Microsoft/Activision) and defining a narrow relevant market around focused competition between the two merging parties that operated within a broader industry (Booz Allen Hamilton/EverWatch). The Agencies have had a strong record in court or in obtaining abandonments in traditional horizontal merger cases in well-defined product markets where the case law supports a presumption against a transaction creating high market shares. However, when the Agencies move beyond that well-established framework, they have far less success in challenging transactions.

    Under the new Merger Guidelines, it is important for companies to assess the risk profiles of their transactions. This includes evaluating whether the Agencies are likely to focus on the transaction and investigate it closely, whether the Agencies are likely to challenge the transaction, and whether they are likely to win if they do challenge it.

    Our experienced team at McDermott helps companies work through these issues every day, and we can help companies assess that risk and defend lawful transactions at the Agencies and, when necessary, in court. We also regularly help companies whose business interests are threatened by transactions involving their competitors or suppliers, and these Merger Guidelines create new opportunities to take such issues to the Agencies.

    Authors

    Jon B. Dubrow

    Partner

    Washington, DC

    Raymond A. Jacobsen , Jr.

    Partner

    Washington, DC

    Ryan C. Tisch

    Partner

    Washington, DC

    Joel R. Grosberg

    Partner

    Washington, DC

    More insights

  • Healthcare Payors and Providers and AI Companies Commit to “Safe, Secure, and Trustworthy” AI Deployment and Use

    Healthcare Payors and Providers and AI Companies Commit to “Safe, Secure, and Trustworthy” AI Deployment and Use

    ARTICLE / CLIENT ALERT

    Healthcare Payors and Providers and AI Companies Commit to “Safe, Secure, and Trustworthy” AI Deployment and Use

    December 21, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Following the White House’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence, on December 13, 2023, the White House spotlighted that 28 healthcare payors and providers intend to implement and adhere to voluntary commitments for the safe, secure and trustworthy development and deployment of artificial intelligence (AI) in healthcare. The commitments by healthcare providers and payors follow those of 15 AI companies to develop AI models responsibly.

    In depth

    The signatory companies, as part of the initiative led and organized by the Coalition for Health AI, aligned around the FAVES principle—namely, that AI should lead to healthcare outcomes that are fair, appropriate, valid, effective and safe. These companies committed to:

    • Informing users when they receive content that is largely AI-generated and not reviewed or edited by people
    • Adhering to a risk management framework for using applications powered by foundation models
    • Pledging to investigate and develop valuable uses of AI responsibly, including creating solutions that advance health equity, expand access to care, create affordable care, coordinate to improve outcomes, reduce clinician burnout and improve patients’ experience

    The White House noted that the use of AI-enabled tools for clinical decisions requires proper oversight, including appropriate testing, risk mitigation and human oversight. The White House further noted that, if entities are able to mitigate risks (e.g., gender or racial bias, or costly errors when used as clinical decision tools), AI carries enormous benefits to patients, doctors and hospital staff.

    KEY TAKEAWAYS

    • Privacy: The White House noted that AI’s ability to collect and infer new information from different data points could create privacy risks for patients
    • Efficiency: The White House acknowledged that AI could help doctors analyze images more quickly and effectively, streamline drug development, and streamline and improve patient administrative processes, including completing patient forms
    • Equity and Accessibility: While AI has the potential to positively impact healthcare outcomes for patients, as well as improve the lives of healthcare providers, the White House emphasized the need to place equity and accessibility at the front and center of AI development

    The White House acknowledged these commitments are a critical step in society’s effort to advance AI for the health and well-being of Americans, and it expressed hope that more private-sector companies will join these commitments in the weeks ahead.

    Companies that develop, purchase or implement AI-enabled technology for their own healthcare-related use cases should consider implementing the FAVES principle into their AI governance framework and company best practices, as well as ongoing development and deployment efforts.

    If your organization has questions about signing on to the pledge or about the FAVES principle, including its potential impacts on the utilization of AI within your healthcare activities, please reach out to your McDermott lawyer or one of the contacts listed below. Visit our AI in Healthcare Resource Center for more health AI updates.

    Authors

    Jennifer S. Geetter

    Partner

    Washington, DC

    Jayda Greco

    Partner

    Chicago

    More insights

  • Corporate Transparency Act Imposes New Federal Reporting Requirements for Renewable Energy Developers, Energy Transition Private Equity Funds and Sustainable Infrastructure Funds

    Corporate Transparency Act Imposes New Federal Reporting Requirements for Renewable Energy Developers, Energy Transition Private Equity Funds and Sustainable Infrastructure Funds

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Imposes New Federal Reporting Requirements for Renewable Energy Developers, Energy Transition Private Equity Funds and Sustainable Infrastructure Funds

    December 20, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The Corporate Transparency Act (CTA) introduces beneficial ownership reporting requirements effective January 1, 2024, for new and existing companies. The CTA reporting obligations also impact due diligence for mergers and acquisitions (M&A) and in-house formation of new entities. It is especially relevant for renewable energy project developers, energy transition private equity funds and sustainable infrastructure funds due to the fact that renewable energy developers often have a complex corporate structure of holding companies and project companies that are often further siloed across technologies such as solar, wind and storage. Each renewable energy project, therefore, has its own separate project company, its intermediate entities and, ultimately, the parent that will need to comply with the CTA. We note that the CTA does not permit a single parent company to submit a single filing covering all its subsidiaries in the aggregate. Instead, each entity will require its own separate beneficial ownership analysis and its own separate CTA filing.

    KEY TAKEAWAYS

    • The CTA introduces beneficial ownership reporting requirements effective January 1, 2024, for new and existing companies.
    • The CTA does not permit a single parent company to submit an aggregate filing covering all of its subsidiaries.
    • Under the CTA, each entity will require its own beneficial ownership analysis and its own separate filing.
    • Developers and sponsors often have complicated corporate structures with numerous entities and beneficial owners. The CTA requires a separate report to be filed for each reporting company unless an exemption applies—which could require developers and sponsors to file dozens, if not hundreds, of reports by the January 1, 2025, deadline for existing companies.
    • In addition, these CTA reporting obligations create a new diligence and process items for M&A transactions, with buyers and sellers now needing to address the pre- and post-closing implications of CTA reporting obligations for the companies involved in the transaction, such as identifying a target company’s compliance and filing updated CTA reports for acquired companies post-closing.
    • Developers and sponsors should move quickly to identify applicable exemptions and relevant beneficial owners for their reporting companies.

    Companies formed by filing a document in any US jurisdiction, or a non-US company registered to do business in any US jurisdiction—and which do not meet one of the 23 exemptions—must report company information and beneficial owner information (and also, for new companies, company applicant information) to the US Department of Treasury’s Financial Crimes Enforcement Network—this information will not be publicly available but can be accessed by certain governmental authorities. Reporting companies formed/registered before January 1, 2024, must file their initial report by January 1, 2025, and reporting companies formed/registered on or after January 1, 2024, must file their initial report within 90 days following such formation/registration (and, starting January 1, 2025, this 90-day period is reduced to 30 days)—updated reports must be filed within 30 days following a change to reported information.

    To obtain answers to frequently asked questions about the new reporting guidelines, read our Corporate Transparency Act: What to Know On the Subject.

    McDermott lawyers are available to help assess reporting obligations, eligibility for exemptions and compliance requirements and provide guidance on M&A transactions, corporate structuring and best practices under the CTA’s new reporting regime.

    In depth
    Authors

    Carl J. Fleming

    Partner

    Washington, DC

    Nathan E. Barnett

    Partner

    Wilmington

    More insights

  • Last-Minute IRS Guidance Leaves Little Time for Long-Term, Part-Time Employee Changes

    Last-Minute IRS Guidance Leaves Little Time for Long-Term, Part-Time Employee Changes

    ARTICLE / CLIENT ALERT

    Last-Minute IRS Guidance Leaves Little Time for Long-Term, Part-Time Employee Changes

    December 19, 2023

    Read time: 5 min

    Key takeaways
    Overview

    Together, the SECURE Act and the SECURE 2.0 Act feature numerous changes to retirement plan rules that aim to help employees achieve retirement security by ensuring that more workers have access to retirement plans, can save enough money to maintain their standard of living in retirement and do not outlive their retirement savings.

    Consistent with this goal, these laws broadened the retirement plan minimum eligibility rules—i.e., the rules that govern how long employees can be asked to wait before joining an employer’s retirement plan—to ensure that long-term, part-time employees can participate in employer 401(k) plans beginning as early as January 1, 2024, and 403(b) plans beginning as early as January 1, 2025. This means employers with 401(k) and 403(b) plans that rely on current rules to exclude employees from plan participation until the employees complete 1,000 hours of service in a year will need to change their enrollment processes to allow long-term, part-time employees to participate under this new rule.

    In depth

    Though well-intentioned, implementing the new rule has been fraught with complexity, driven in part by long-unanswered questions about how the requirement should be applied. Recently issued guidance provides insight about the rule and answers to many of those unanswered questions by:

    • Reminding employers that long-term, part-time employees include employees who work at least 500 hours for three consecutive years (reduced to two beginning January 1, 2025) and meet the minimum age requirement to participate in the plan;
    • Explaining that employers that maintain 401(k) or 403(b) plans must provide such employees the opportunity to make elective deferrals permitted by their plans, but they need not provide corresponding opportunities to receive employer contributions until the employees satisfy the regular plan rules;
    • Noting that the new rule does not apply to collectively bargained plans but does apply (subject to a request for further comments) to governmental plans and church plans;
    • Clarifying that the new long-term, part-time employee rule does not apply to plans that use elapsed time (rather than hours) to determine eligibility;
    • Confirming that employers can continue to exclude reasonable classifications of employees, even if those employees would otherwise be eligible to participate as long-term, part-time employees, provided the exclusions are not based on age or service;
    • Advising that service must be counted for purposes of satisfying the 500-hour rule for years beginning with 2021 (for 401(k) plans) and 2023 (for 403(b) plans);
    • Clarifying that employers can track hours for purposes of this rule using previously permitted equivalencies (e.g., 190 hours of service for each month)—there is no special equivalency rule for long-term, part-time employees—rather than actual hours;
    • Clarifying that the same eligibility computation period and entry date requirements apply to regular employees and long-term, part-time employees, meaning employers may use anniversary year or plan year measurement periods, and must have at least semiannual entry dates to allow employees to enter the plan after satisfying the eligibility requirements;
    • Advising that once a long-term, part-time employee becomes a participant by virtue of satisfying the required service period, the employee will remain in the plan even if the employee’s service level falls below 500 hours per year;
    • Explaining that a long-term, part-time employee is required to be credited with a year of vesting service if the employee completes 500 hours of service, and that this lower hours threshold continues to apply even if the long-term, part-time employee later becomes a full(er)-time employee;
    • Confirming that employers with safe harbor plans can choose not to make safe harbor contributions to long-term, part-time employees without jeopardizing the safe harbor status of their plans, but the exclusion must be set forth in the plan; and
    • Confirming that employers may elect to exclude long-term part-time, employees from annual coverage and nondiscrimination testing, and from receipt of any required top-heavy contributions or vesting.

    The new guidance provides much-needed clarity around several key issues related to the treatment of long-term, part-time employees. However, with that new rule effective for 401(k) plans beginning January 1, 2024, the guidance leaves employers very little time to make changes to how their human resources information system providers and recordkeepers currently track hours for this purpose. As a result, it is imperative that employers review their existing eligibility-tracking processes as soon as possible to determine if changes are needed. Some employers may also want to continue exploring design changes that would help reduce the administrative burden associated with complying with the new rules.

    For any questions regarding SECURE 2.0 changes, please contact your regular McDermott lawyer or one of the authors.

    Authors

    Brian J. Tiemann

    Partner

    Chicago

    Haley M. Dow

    Associate

    Chicago

    More insights

  • California’s New Climate Disclosure Laws: What You Need to Know

    California’s New Climate Disclosure Laws: What You Need to Know

    ARTICLE / CLIENT ALERT

    California’s New Climate Disclosure Laws: What You Need to Know

    December 19, 2023

    Read time: 11 min

    Key takeaways
    Overview

    While the highly anticipated adoption of proposed rules on climate risk disclosure by the US Securities and Exchange Commission (SEC) appears to be on hold (the SEC’s recently revised regulatory agenda indicates possible adoption no sooner than the second quarter of 2024), expansive international and subnational regulation of climate risk disclosure by both public and private companies is well underway. SEC Chairman Gary Gensler has warned that the absence of US climate risk disclosure rules might mean that US companies could face more onerous disclosure requirements without an opportunity for the SEC to negotiate “substituted compliance” with non-US regulators on the basis of mandatory comparable regulation in the United States.

    Internationally, as discussed in depth in our International News: Spotlight on ESG, Impact and Sustainability report, new climate risk disclosure requirements include the European Union’s reporting standards that were adopted last summer and specify the sustainability information that will be required to be reported under the EU Corporate Sustainability Reporting Directive, including by non-European companies with significant European operations, and the climate-related and general sustainability standards of the International Sustainability Standard Board (ISSB), which were also adopted this past year.

    In the US, on October 7, 2023, California Governor Gavin Newsom signed three new climate disclosure bills detailed below. In one instance, the legislation notes the pendency of the SEC’s proposed rules, stating that “California has an opportunity to set mandatory and comprehensive risk disclosure requirements for public and private entities to ensure a sustainable, resilient and prosperous future for our state.”

    In depth

    The new laws—Senate Bill (SB) 253: Climate Corporate Data Accountability Act, SB 261: Greenhouse gases: climate-related financial risk and Assembly Bill (AB) 1305: Voluntary carbon market disclosures—will require certain entities doing business in California to:

    • Measure and report their greenhouse gas (GHG) emissions
    • Report their climate-related financial risks, governance, strategies, goals and metrics
    • Disclose information about the basis of any published statements regarding net zero or carbon neutrality goals or achievements.

    In their totality, these laws will have the effect of mandating comprehensive reporting of climate-related information to the public. There will likely be changes to these groundbreaking climate disclosure laws for several reasons: the California Air Resources Board (CARB) will promulgate regulations, Governor Newsom pledged to work with the legislature during the 2024 legislative session to amend the implementation requirements to provide more time for compliance, and litigation challenging the laws is expected.

    SB 253

    SB 253 requires reporting entities to measure and report their GHG emissions. A reporting entity is defined as any business entity doing business in California that has a total annual revenue of more than $1 billion. The statute, as currently enacted, appears not to contemplate any exemptions based on whether a parent company is a reporting entity, suggesting the possibility that multiple affiliated entities could be required to each make separate individual reports. This issue may be addressed in CARB’s forthcoming regulations. While SB 253 does not define “doing business in California,” a definition or reference to one in another California law is likely to be included in regulations promulgated by CARB prior to January 1, 2025, as the legislative history of SB 253 notes that “doing business in California” is already defined in existing law as “actively engaging in any transaction for the purpose of financial or pecuniary gain or profit.”

    Scope 1, scope 2 and scope 3 GHG emissions are defined by SB 253 as follows:

    • Scope 1 means all direct GHG emissions stemming from sources that a reporting entity owns or directly controls, regardless of location, including (but not limited to) fuel combustion activities.
    • Scope 2 means indirect GHG emissions from consumed electricity, steam, heating or cooling purchased or acquired by a reporting entity, regardless of location.
    • Scope 3 means indirect upstream and downstream GHG emissions, other than scope 2 emissions, from sources that the reporting entity does not own or directly control, including (but not limited to) purchased goods and services, business travel, employee commutes and processing and use of sold products.

    SB 253 requires that starting in 2026, on or by a date to be determined by CARB and annually thereafter, reporting entities must measure and publicly report their scope 1 and scope 2 GHG emissions in conformance with the protocol standards and guidance in “The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard” and the “Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standard,” developed by the World Resources Institute and the World Business Council for Sustainable Development. Further, SB 253 requires that starting in 2027 and annually thereafter, reporting entities must disclose their scope 3 GHG emissions no later than 180 days after disclosure of their scope 1 and scope 2 GHG emissions.

    Third-party assurance must be provided with respect to the GHG emissions disclosures required by SB 253. Starting with the scope 1 and scope 2 disclosures in 2026, limited assurance must be performed by a third-party assurance provider who has significant experience in measuring, analyzing, reporting or attesting to the GHG emissions. Scope 1 and scope 2 disclosures will require reasonable assurance starting in 2030. SB 253 currently requires that limited assurance be obtained for scope 3 disclosures starting in 2030, however, SB 253 allows CARB to require limited assurance for scope 3 disclosures at any time after January 1, 2027.

    As currently enacted, SB 253 does not define what constitutes “limited” or “reasonable” assurance. CARB could include clarification in forthcoming regulations. The SEC’s proposal would require public companies to report GHG emissions and includes explanations of “limited” and “reasonable” assurance, which may provide guidance in the absence of a specific regulatory definition in California. The SEC, in proposed rulemaking, noted that reasonable assurance “is equivalent to the level of assurance provided in an audit of a registrant’s consolidated financial statements included in a Form 10-K.”[1] The SEC’s proposal also suggested that limited assurance “is equivalent to the level of assurance (commonly referred to as a ‘review’) provided over a registrant’s interim financial statements included in a Form 10-Q.”[2]

    SB 253 authorizes administrative penalties of up to $500,000 per year for non-filing, late filing or other failures to meet the requirements (including misstatement of scope 1 and scope 2 disclosures as described below). No penalties may be assessed for any “misstatements with regard to scope 3 emissions disclosures made with a reasonable basis and disclosed in good faith.” With respect to scope 3 emissions, only non-filing penalties may be assessed between 2027 and 2030. Again, no regulations have yet been issued on this subject, but the statutory limits on penalties assessed for misstatements of scope 3 disclosures suggests that penalties could be assessed against misstatements of scope 1 and scope 2 disclosures.

    SB 261

    SB 261 requires covered entities to prepare, publish and submit a climate-related financial risk report on or before January 1, 2026, and biennially thereafter. The definition of a “covered entity” tracks the definition of a “reporting entity” under SB 253. A covered entity under SB 261 is a business entity that is doing business in California and has a total annual revenue exceeding $500 million. The lower revenue threshold implies greater applicability of SB 261. Much like in SB 253, the applicability of SB 261 will hinge largely upon the phrase “doing business in California,” which SB 261 does not define. While this criterion applies to individual legal entities, if a subsidiary of a covered entity also qualifies as a covered entity, the subsidiary does not need to prepare a separate report.

    The reporting obligation that SB 261 imposes on covered entities is twofold: the covered entity must publish the report on its website and file the report with CARB. Reports prepared pursuant to SB 261 must disclose (1) climate-related financial risks[3] and (2) measures adopted to address the risks disclosed. The climate-related financial risks must be disclosed in accordance with either:

    • The disclosure framework set forth in the Task Force on Climate-Related Financial Disclosures’ (TCFD) Final Report of Recommendations or any successor frameworks
    • Any other reports required by law in other jurisdictions that incorporate disclosure requirements consistent with the TCFD’s framework or any successor frameworks
      • Under SB 261 as enacted and in the absence of CARB regulations, it is unclear how consistent these other reports must be with the TCFD framework to satisfy the reporting obligation.
    • ISSB’s International Financial Reporting Standards (IFRS) Sustainability Disclosure Standards.
      • With the publication of ISSB Standards IFRS S1 and IFRS S2, which fully incorporated the TCFD recommendation, the Financial Stability Board noted that the standards were the “culmination of the work of the TCFD” and moved to disband the TCFD, passing monitoring responsibilities to ISSB starting in 2024. The ISSB Standards may be viewed as a successor framework to the TCFD.

    Under SB 261, CARB is authorized to promulgate regulations authorizing the assessment of penalties of up to $50,000 per year for failure to report or for reporting inadequate or insufficient information.

    AB 1305

    Beginning January 1, 2024, AB 1305 requires reporting for entities “operating in”[4] California that make claims within California that include (Covered Claims):

    • Statements regarding the achievement of net zero emissions[5]
    • Statements that the entity, a related or affiliated entity, or a product is “carbon neutral”
    • Statements implying the entity, a related or affiliated entity, or a product does not add net carbon dioxide (CO2) or GHG emissions to the climate or has made significant reductions to its CO2 or GHG emissions.

    Under AB 1305, entities must disclose “all information” documenting how a Covered Claim was determined to be accurate and how interim progress toward such goal stated in the Covered Claim is being measured. AB 1305 suggests that such information may include:

    • Disclosure of independent third-party verification of all of the entity’s GHG emissions
    • Identification of the entity’s science-based targets for its emissions reduction pathway
    • Disclosure of the relevant sector methodology and third-party verification used for the entity’s science-based targets and emissions reduction pathway
    • Any third-party verification of the data listed and of the Covered Claim.

    Notably, AB 1305 does not apply to entities that do not “operate in” California or to claims not made “within” California.[6] Disclosures related to Covered Claims must be updated annually. Violations of AB 1305 are subject to potential monetary penalties of up to $500,000. Additionally, AB 1305 requires disclosure from entities that market, sell, purchase or use voluntary carbon emissions offsets in California.

    HOW TO PREPARE

    Evaluate Statements With Respect to Net Zero, Carbon Neutrality or Emissions Reduction

    AB 1305’s reporting requirements take effect on January 1, 2024. Given the immediacy of this approaching effective date, any statements relating to an entity’s emissions, emissions reduction or carbon neutrality should be identified. To the extent any statements are identified, all information related to the making of such statements should be collected and be made publicly available. Policies requiring public statements to be reviewed for Covered Claims can help to ensure compliance going forward.

    Develop Internal Expertise Regarding Climate Reporting

    California’s new laws, as well as proposed and enacted rules from the SEC and in other jurisdictions, will require some level of climate disclosure. Reporting entities will need to be familiar not only with the multitude of frameworks and standards (Greenhouse Gas Protocol, TCFD, ISSB, etc.), but also how these frameworks and standards are applied differently across each jurisdiction. This reporting will require measuring emissions of various climate warming gasses and analyzing climate-related risks such as physical risks and transition risks. Entities required to report under one or more reporting regimes can start building competence around climate information now, allowing them to meet upcoming disclosure obligations.

    Prepare to Coordinate Collection and Consistent Reporting of Climate Data

    Coordinating the data that is collected and reported will be crucial as companies begin to comply with multiple reporting regimes. Cross-functional teams should be formed, and policies should be developed to ensure that data is collected as efficiently and accurately as possible and that reports are consistent in using that information. For example, SB 253 requires disclosure of scope 3 emissions, however, the SEC’s proposed rules require scope 3 emissions to be disclosed if they are material. Entities reporting scope 3 emissions that are significantly greater than scope 1 and scope 2 emissions may struggle to claim that these are immaterial in SEC filings.

    Identify Third-Party Assurers and Advisors With Relevant Expertise

    Given that SB 253 requires assurance of disclosures, third-party assurance providers should be identified and engaged on a timely basis. These assurance providers and other third-party providers can assist in controls and structures to support climate disclosure as well as with developing data collection mechanisms.

    For more information, please contact your regular McDermott lawyer or David Cifrino or Stephen Aber.

    Authors

    David A. Cifrino

    Counsel

    Boston

    Stephen Aber

    Law Clerk

    Boston

    More insights

  • Medicare Provider and Supplier Enrollment Requirements: Program Integrity Changes for 2024

    Medicare Provider and Supplier Enrollment Requirements: Program Integrity Changes for 2024

    ARTICLE / CLIENT ALERT

    Medicare Provider and Supplier Enrollment Requirements: Program Integrity Changes for 2024

    December 19, 2023

    Read time: 16 min

    Key takeaways
    Overview

    The US Centers for Medicare & Medicaid Services (CMS) finalized important changes to the Medicare provider and supplier enrollment regulations, including adding marriage and family therapists (MFTs) and mental health counselors (MHCs) as supplier types eligible for enrollment. Other enrollment changes include increasing CMS’ authority to deny or revoke enrollments and deactivate providers’ billing privileges after six months of non-billing and creating a new “stay of enrollment” status. Providers also will be required to report changes in practice locations within 30 days.

    In depth

    BACKGROUND

    To receive Medicare reimbursement for providing services to Medicare beneficiaries, healthcare providers and suppliers are required to enroll in the Medicare program. Medicare providers and suppliers are required to continuously satisfy enrollment regulations applicable to the specific Medicare provider or supplier type, including making any necessary updates to the provider’s or supplier’s enrollment file in order to receive Medicare reimbursement.

    These regulations are intended to promote program integrity and ensure that Medicare providers and suppliers are operating in accordance with program requirements. CMS and Medicare Administrative Contractors (MACs) are permitted to take proactive action against providers and suppliers engaging (or potentially engaging) in fraudulent or abusive behavior who present a risk of harm to Medicare beneficiaries or that are otherwise unqualified to furnish Medicare services or items. Consistent with these continuing policy goals, CMS finalized changes to the Medicare enrollment regulations for a variety of provider and supplier types in the CY 2024 Medicare Physician Fee Schedule Final Rule (MPFS Rule) and the CY 2024 Home Health Prospective Payment System Final Rule (Home Health Rule).

    KEY MEDICARE ENROLLMENT CHANGES

    CMS Expands Its Authority to Revoke or Deny Enrollment in the Medicare Program

    CMS has the authority to revoke a Medicare provider’s or supplier’s enrollment for a variety of reasons, including the provider’s or supplier’s failure to adhere to Medicare enrollment requirements, exclusion by the Office of Inspector General (OIG), and felony convictions, among other bases. When a provider or supplier is revoked, the provider or supplier is generally barred from reenrolling in Medicare for a period of one to 10 years, based on the severity of the basis for revocation. Similarly, CMS may deny a newly enrolling provider’s or supplier’s enrollment for any of the listed reasons. Below is a summary of CMS’s expansion of its revocation and denial authority.

    • The existing regulation, 42 C.F.R. § 424.535(a)(1), permits revocation if the provider or supplier is determined to be out of compliance with applicable enrollment requirements or in the enrollment application for the provider or supplier type. The MPFS Rule changes this to noncompliance with the enrollment requirements described in “title 42, or the enrollment application” to account for enrollment requirements located outside of 42 C.F.R. part 424, subpart P.
    • False Claims Act judgments. The MPFS Rule adds civil judgment under the False Claims Act (FCA) against any provider or supplier, owner, managing employee or organization, officer, or director within the previous 10 years as a basis for enrollment denial or revocation. The term “civil judgment” does not include FCA settlement agreements.
    • Violation of provider and supplier standards. The MPFS Rule provides CMS with broad authority to deny or revoke an independent diagnostic testing facility’s (IDTF), durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) supplier’s, opioid treatment program’s (OTP), home infusion therapy (HIT) supplier’s, or Medicare diabetes prevention program’s (MDPP) enrollment for a violation of any standard or condition listed in the respective IDTF, DMEPOS supplier, OTP, HIT supplier, and MDPP enrollment standards and conditions.
    • Existing debt. Currently, CMS may revoke enrollment if the provider or supplier has an existing debt that CMS appropriately refers to the US Department of the Treasury. The MPFS Rule replaces the term “existing debt” with “failure to repay a debt.” This change allows CMS to use its revocation authority even if collection action has ceased and the debt was ultimately terminated as a result, reflecting focus on the provider’s or supplier’s inaction in fulfilling its financial obligations to Medicare rather than the particular status or result of CMS’ collection efforts. CMS will exclude certain situations from the purview of this revocation basis.

    Revocation Effective Date

    Currently, a Medicare enrollment revocation becomes effective 30 days after CMS or the MAC mails notice of its determination to the provider or supplier, except when the revocation is based on a federal exclusion or debarment, felony conviction, license suspension or revocation, or non-operational practice location. With each of these circumstances, the revocation is effective on the date of exclusion or debarment, felony conviction, license suspension or revocation, or the date that CMS or the MAC determined that the provider or supplier was non-operational.

    In addition to these circumstances, CMS has modified the applicable regulations to specify the following circumstances where a retroactive effective date is warranted:

    • Revocations based on a state license surrender in lieu of further disciplinary action, to be effective the date of the license surrender
    • Revocations based on termination from a federal healthcare program other than Medicare (for example, Medicaid), to be effective the date of the termination
    • Revocations based on termination of a Medicare provider agreement, to be effective (depending on the provider type) on the later of the following: (1) the date of the provider agreement termination or (2) as applicable, the date that CMS establishes under 42 C.F.R. § 489.55
    • Revocations of an IDTF, DMEPOS supplier, OTP, HIT supplier or MDPP’s enrollment for a violation of any standard or condition listed in the respective IDTF, DMEPOS supplier, OTP, HIT supplier and MDPP enrollment standards and conditions, to be effective as follows:
      • If the standard or condition violation involved the suspension, revocation or termination (or surrender in lieu of further disciplinary action) of the provider’s or supplier’s federal or state license, certification, accreditation or MDPP recognition, the revocation effective date would be the date of the license, certification, accreditation or MDPP recognition suspension, revocation, termination or surrender.
      • If the standard or condition violation involved a non-operational practice location (for example, an IDTF’s failure to maintain a physical facility on an appropriate site), the revocation effective date would be the date the non-operational status began.
      • If the standard violation involved a felony conviction of an individual or entity, the revocation effective date would be the date of the felony conviction.

    Timeframes for Reversing a Revocation

    Currently, if a revocation is due to adverse activity (i.e., sanction, exclusion or felony) by certain parties, such as an owner, managing employee, authorized or delegated official, or supervising physician, the revocation can be reversed if the provider or supplier terminates (and submits proof that it has terminated) its business relationship with that party within 30 days of the revocation notification. The MPFS Rule reduces this timeframe to 15 days.

    Reporting Changes in Practice Location

    Under current Medicare regulations, certain suppliers and providers (including DMEPOS suppliers, IDTFs, and physicians, nonphysician practitioners, and physician and nonphysician practitioner organizations) must report any changes of practice location as an enrollment update within 30 days of the change. All other provider types are required to report changes of location within 90 days. The MPFS Rule revises this requirement to require all Medicare provider and supplier types to report changes of location within 30 days of the effective date of the change. CMS also clarified that a “change of practice location” includes additions of a new location and deletion of an existing location.

    Creation of a New Provider Enrollment Status: “Stay of Enrollment”

    Current regulations allow CMS to deactivate a provider’s or supplier’s Medicare billing privileges pursuant to specified reasons, which is often used instead of a revocation when CMS believes a more modest sanction is warranted. However, deactivations still impose potential burdens on providers and suppliers, including a prohibition on receiving payment for services and items while deactivated. Out of concern that deactivation of billing, while less severe than revocation, may be too punitive in certain cases, the MPFS Rule adopts a new enrollment status referred to as a “stay of enrollment.” This is a preliminary, interim status—prior to any subsequent deactivation or revocation—in which the provider or supplier remains enrolled in Medicare. CMS’s authority to impose a stay is discretionary, and the agency could elect to proceed directly to deactivation or revocation, if desired. The stay period will have a definitive timeframe of no more than 60 days from the postmark date of the notification letter. The stay’s end date will be the date on which CMS or the MAC determines that the provider or supplier has resumed compliance with all Medicare enrollment requirements or the day after the 60-day stay period expires, whichever occurs first. In response to comments, CMS declined to provide guidance regarding the types of conduct that would result in a (1) deactivation, (2) a stay of enrollment or (3) no CMS action. However, CMS indicated that the stay provision is not primarily intended to penalize providers for matters that previously would not have involved CMS action; rather, it is intended to reduce the severity of CMS action for minor cases of noncompliance that would ordinarily have triggered a deactivation.

    The MPFS Rule adopts two prerequisites to implementing a stay of enrollment. First, there must be actual noncompliance with at least one enrollment requirement. Second, CMS must ascertain that the provider or supplier can remedy the noncompliance via the submission of an appropriate Medicare enrollment application, change of information or revalidation application (depending on the circumstances).

    CMS will provide the provider or supplier with written notice regarding the stay of enrollment. During the stay period, claims submitted by the provider or supplier services or items furnished during the period will be rejected. However, these claims are eligible for payment (and may be resubmitted by the provider or supplier within applicable timeframes) if (1) CMS or the MAC determines that the provider or supplier has resumed compliance with all Medicare enrollment requirements and (2) the stay ends on or before the 60th day of the stay period.

    CMS states the stay of enrollment is also different from deactivation, in that MACs can process change requests more rapidly than reactivation applications, allowing payments to resume sooner. In addition, the completion of a change request is less burdensome than the completion of a reactivation application. The MPFS Rule also adopts a rebuttal process, which will largely align with the existing rebuttal processes for deactivations and payment suspensions.

    Definitions

    The MPFS Rule adopts new and clarified definitions to help explain the meaning of certain provider enrollment concepts. These includes clarified definitions of “indirect ownership” and “authorized official.”

    Retroactive Provider Agreement Terminations

    A provider that holds a provider agreement in addition to its Medicare enrollment may voluntarily terminate its provider agreement and stop participating in the Medicare program. Under existing sub-regulatory guidance, a provider may request a retroactive termination effective date (for example, retroactive to the date the provider’s facility closed). To implement and incorporate this practice into regulation, CMS adopted a provision stating that providers may request a retroactive termination date, but only if no Medicare beneficiary received services from the facility on or after the requested termination date.

    Deactivation for Non-Billing

    Current regulations allow CMS to deactivate a provider’s or suppliers’ billing privileges when the provider or suppler has not submitted any Medicare claims for 12 consecutive months. In the Home Health Rule, CMS finalized a reduction in this time period to six months, permitting CMS to deactivate a provider’s or supplier’s billing privileges more quickly. This change was driven by CMS’ concerns regarding fraud schemes that involved providers utilizing multiple enrollments to inappropriately avoid overpayment obligations or to circumvent investigations, as well as situations where an inactive provider number is used by a third party to fraudulently bill Medicare for services. CMS recognized that certain lengthy periods of non-billing may not necessarily involve any improper provider activity; for example, some providers must be enrolled in Medicare to enroll in Medicaid; in these circumstances, the provider may not intend to bill Medicare, resulting in an extended period of Medicare non-billing. CMS finalized this change and now has discretionary authority to deactivate a provider for six months of non-billing. CMS noted that providers and suppliers that have not been deactivated for 12 months of non-billing should not assume they are more likely to be deactivated based on this change.

    Fingerprint-Based Criminal Background Checks for High-Risk Provider and Supplier Types

    During the COVID-19 public health emergency (PHE), CMS temporarily waived the requirement for fingerprint-based criminal background checks for individuals who own 5% or more of newly enrolling providers and suppliers who are categorized as “high-risk” providers or suppliers. This “high risk” category includes home health agencies (HHAs), DMEPOS suppliers, MDPP suppliers, certain OTPs, and skilled nursing facilities (SNFs). Due to concerns about the lack of background checks conducted during the PHE, CMS implemented a change in the requirements applicable to DMEPOS suppliers, HHAs, OTPs, MDPPs and SNFs through the revalidation process. For these high-risk provider and supplier types that were not required to have a background check when the provider or supplier initially enrolled during the PHE, the provider or supplier will be required to have any owners holding 5% or more of the entity undergo a fingerprint-based criminal background check in order for the provider or supplier to revalidate its Medicare enrollment. To account for future emergencies under which CMS may waive background checks, the regulations provide that revalidating DMEPOS suppliers, HHAs, OTPs, MDPPs, SNFs and hospices that are subject to a waiver of the background check requirements during their initial enrollment due to a national, state or local emergency will be deemed to be a high-risk provider or supplier for purposes of their revalidation. Practically speaking, these provisions are intended to ensure that CMS can require fingerprint-based criminal background checks for providers and suppliers who were subject to the PHE waiver of these requirements, or for providers and suppliers who may be able to enroll during a future waiver of these background check requirements. In addition to revising and clarifying the regulations related to background checks, CMS clarified that it reserves the right to conduct off-cycle revalidations of high-risk providers and suppliers who may have been able to enroll without a fingerprint-based criminal background check during the PHE.

    Expansion of Reapplication Bar

    Currently, CMS may prohibit a prospective provider or supplier from enrolling in Medicare for up to three years if the enrollment application is denied because the provider or supplier submitted false or misleading information on or with (or omitted information from) the enrollment application. CMS now has authority to extend the maximum length of the reapplication bar to 10 years to account for provider or supplier conduct of particular severity.

    Ordering, Referring, Certifying and Prescribing Restrictions

    Continuing with the theme of adding restrictions to prevent providers and suppliers who may have engaged in dishonest or felonious activity from reenrolling or otherwise being able to bill Medicare, CMS has established new regulations intended to prevent certain providers and suppliers from being able to order, refer, certify or prescribe Medicare-covered services, items or drugs. Specifically, a provider or supplier that is currently subject to a reapplication bar is not permitted to order, refer, certify or prescribe Medicare-covered services, items or drugs. To enforce this provision, the rule further adopts a provision stating that Medicare does not pay for any otherwise covered service, item or drug that is ordered, referred, certified or prescribed by a provider or supplier that is currently under a reapplication bar. Additionally, a physician or other eligible professional (regardless of whether they are or were enrolled in Medicare) who has had a felony conviction within the previous 10 years may not order, refer, certify or prescribe Medicare-covered services, items or drugs. With respect to a provider or supplier with a felony conviction, CMS has authority to enforce this prohibition for any felony that CMS determines is detrimental to the best interests of the Medicare program and its beneficiaries. CMS declined to adopt a consistent, defined list of felony convictions that it deems detrimental to Medicare and stated that the agency retains the flexibility to consider each felony case on its own facts and circumstances.

    New Mental Health Professional Supplier Types Established

    In the Consolidated Appropriations Act of 2023 (CAA), the US Congress established a new Medicare Part B benefit category for services provided by MFTs and MHCs. Consistent with the CAA, the MPFS Rule implements regulations that allow MFTs and MHCs to bill for the diagnosis and treatment of patients with mental illnesses and establishes requirements for these new professional types.

    CMS finalized a regulatory definition for a “marriage and family therapist” as an individual who: (1) possesses a master’s or doctoral degree that qualifies them for licensure or certification as a MFT pursuant to state laws of the state in which they provide services; (2) has performed at least two years or 3,000 hours of post-master’s degree clinical supervised experience in marriage and family therapy in an appropriate setting, such as a hospital, SNF, private practice, or clinic; and (3) is licensed and certified as an MFT by the state in which they provide services.

    Similarly, “mental health counselor” is defined as an individual who: (1) possesses a master’s or doctoral degree that qualifies for licensure or certification as an MHC, clinical professional counselor, or professional counselor pursuant to state laws of the state in which they provide services; (2) has performed at least two years or 3,000 hours of post-master’s degree clinical supervised experience in mental health counseling in an appropriate setting, such as a hospital, SNF, private practice, or clinic; and (3) is licensed and certified as an MHC, clinical professional counselor, or professional counselor by the state in which they provide services. In commentary, CMS recognized that states use various terms to describe mental health clinicians, and clarified that individuals who meet all of the applicable statutory and regulatory qualifications for the MHC benefit category for education and clinical supervised experience but are licensed or certified by their state under a different title to provide mental health counseling are eligible to enroll in Medicare under the “mental health counselor” category. This includes addiction and drug counselors.

    MFTs and MHCs are now able to enroll in Medicare via Form CMS-855I. CMS clarified in guidance that MFTs and MHCs cannot begin billing for services until January 1, 2024, and will not be granted an earlier effective date. MFT and MHC supplier types, like most nonphysician practitioner types, will be subject to limited risk screening.

    CONCLUSION

    In the most recent regulatory rulemaking cycle, CMS has continued the trend of strengthening its authority to revoke and limit billing privileges for Medicare providers and suppliers who may not be in compliance with Medicare enrollment and participation requirements. Specifically, these new enrollment requirements affect new and existing Medicare providers and suppliers and create new and ongoing compliance obligations.

    Given the broad authority CMS and MACs have to enforce Medicare enrollment requirements, the potentially harsh consequences for failure to comply with Medicare requirements, and the lengthy and costly appeal process, providers and suppliers should pay careful attention to their Medicare enrollment records and ensure policies and procedures are in place to appropriately report any changes in information that may be required. CMS has indicated that sub-regulatory guidance will be released for stakeholders that will explain these new provider enrollment requirements and the provider and supplier actions required for compliance.

    Authors

    Monica Wallace

    Partner

    Chicago

    Caroline Reignley

    Partner

    Washington, DC

    Grayson I. Dimick

    Associate

    Washington, DC

    More insights

  • Update on Tax, Investment Funds and Real Estate Law – The VAT Exemption for Alternative Investment Funds Is Coming Soon

    Update on Tax, Investment Funds and Real Estate Law – The VAT Exemption for Alternative Investment Funds Is Coming Soon

    ARTICLE / CLIENT ALERT

    Update on Tax, Investment Funds and Real Estate Law – The VAT Exemption for Alternative Investment Funds Is Coming Soon

    18. Dezember, 2023

    Read time: 11 min

    Key takeaways
    Overview

    Management services for alternative investment funds (AIFs) will be free from value-added tax (VAT) starting in 2024. This is good news for Germany as a fund location because there will finally be alignment with the more favorable VAT regulations currently in place for European fund locations, such as Luxembourg. There are important changes at the intersection of tax law, investment funds and real estate law, so AIFs, , alternative investment fund managers (AIFMs), investment advisors and landlords should start preparing now before the changes take effect on January 1, 2024.

    BACKGROUND

    • According to the current legal landscape, management services for (i) Undertakings for Collective Investment in Transferable Securities Directive 2009/65/EC (UCITS) within the meaning of Section 1, Paragraph 2 of the of the “Capital Investment Code (Kapitalanlagegesetzbuch) (KAGB), (ii) AIFs in comparison to those within the meaning of Section 1, Paragraph 3 of the KAGB and (iii) venture capital funds are exempt from VAT (Section 4, Paragraph 8(h) of the Umsatzsteuergesetz (UStG)).
    • For AIFs within the meaning of Section 1, Paragraph 3 of the KAGB, this means that, because of the restrictive interpretation of a comparable AIF by the tax authorities (See Section 4.8.13, Paragraph 8 of the German VAT guidelines), management services provided by the AIFM to an AIF are generally subject to VAT.
    • Because of their passive investment, AIFs are typically not entrepreneurs within the meaning of VAT law. As a result, the VAT on management services is not deductible as input tax by the AIF and therefore leads to definitive costs at the fund level. These are charged either to the investors or the fund managers.
    • The cost aspect was often cited as a disadvantage for Germany as a fund location. In neighboring European countries, particularly Luxembourg, management services for AIFs are generally exempt from VAT.
    • •The extension of the VAT exemption through the German Fund Location Act (BGBl. 2021 I, 1498) as it relates to venture capital funds was seen as a step in the right direction. However, this also came with delimitation difficulties that lead to legal uncertainty in the practical application.

    NEW VAT EXEMPTION FOR AIFS

    • As part of the German Financing for the Future Act (BGBl. I 2023, No. 354), the VAT exemption is now being introduced to AIFs for management services. AIFs and venture capital funds that are “comparable to a UCITS” will be abolished, and a general VAT exemption will be introduced for AIFs. The aim of the new regulation is to create a level playing field between Germany and other European jurisdictions (See BT-Drs. 20/8292, p. 133).
    • The regulation is mandatory, so the VAT exemption cannot be waived.
    • In terms of timing, the new regulation will apply starting January 1, 2024.

    EFFECTS IN PRACTICE

    THE TAX PERSPECTIVE

    • Once the new regulation takes effect, AIFs will receive relevant administrative services from AIFMs as VAT-exempt input transactions. This means that input taxes can no longer be deducted at the fund level.
    • For AIFMs, the new regulation should lead to an increase in VAT-exempt output transactions. (Services provided to an AIF must be examined to determine whether they fall under the VAT exemption.) That increase is relevant for an AIFM’s ability to deduct input tax. Input services directly attributable to administrative services are completely excluded from input tax deductions. For general costs, the input tax deduction is only granted in accordance with the individual input tax key (i.e., the share of output services subject to VAT in the total output services).
    • Under certain conditions, the VAT exemption also applies to management services provided indirectly to an AIF (e.g., certain services provided by an investment advisor in the case of outsourcing who provides advisory services for an AIF to its AIFM.)
    • In the event of advisory services for a foreign fund to its foreign AIFM (e.g., Luxembourg’s fund structure), the same principles apply. Certain other services for an entrepreneur will be VAT-exempt because of the place of performance abroad. However, the VAT exemption on administrative services leads to a (partial) exclusion of an input VAT deduction at the level of the domestic investment advisor if the place of performance is hypothetically in Germany (Section 15, Paragraph 2, Clause 1, Number 2 of the UStG).
    • The output services provided and the impact on the input tax key should be analyzed from the perspective of AIFMs and investment advisors.
    • At the AIFM or investment advisor level, the invoices must also be adjusted for the changed VAT treatment. An incorrect VAT statement (Section 14c, Paragraph 1 of the UStG) will result in paying the incorrectly stated VAT. There is no input tax deduction for an incorrectly stated VAT. If necessary, invoices must be adjusted to show the corrected VAT.

    THE INVESTMENT FUND PERSPECTIVE

    • The new regulation applies to regulated AIFs within the meaning of Section 1, Paragraph 3 of the KAGB and is irrespective of asset classes. It also extends to include relevant management services, like portfolio management and risk management services. Other activities, such as custody, are not included.
    • The elimination of the VAT burden will cause a reduction in costs at the AIF level, which will increase the investment return. Individual remuneration agreements regarding VAT must be reviewed.
    • At the other end of cost reduction at the fund level, there is a reduction in the input tax deduction at the AIFM or investment advisor level, i.e., a definitive cost burden due to a nondeductible VAT on input sales (e.g., advisory services). (For further additional costs, see the real estate perspective below).
    • In the event of existing structures, the fund documentation should be reviewed for any necessary adjustments. For new structures that still need to be set up, fund initiators and AIFMs or fund advisors should take the impact of VAT into account commercially.

    THE REAL ESTATE PERSPECTIVE

    • When it comes to rented offices of the AIFM or the investment advisor, these rental agreements may not be subject to VAT from the landlord’s perspective (the so-called VAT option). For the VAT option to be effective, the tenant must generate at least 95% of its sales subject to VAT. The landlord has an interest in letting subject to VAT if there are current input tax adjustment periods for the property existent and the increase of the VAT-exempt letting may trigger input VAT adjustments for the landlord or a pro rata refusal to deduct current input VAT.  (the so-called input tax damage).
    • The elimination of the VAT option means that the rent will be owed without VAT in future (i.e., VAT-free). However, depending on the provision in the rental agreement, the tenant may be obliged to compensate the landlord for any input tax loss incurred.
    • In the invoice issued to settle the rental agreement (usually in the form of a long-term rental invoice), the VAT statement must be adjusted, if necessary, to avoid liability for an incorrect tax statement (Section 14c, Paragraph 1 of the UStG).
    • Existing lease agreements with AIFMs and investment advisors should be reviewed from the tenant’s and landlord’s perspective for relevance, potential information and compensation obligations as well as adjustment options.
    In depth

    HINTERGRUND

    • Nach derzeit geltender Rechtslage sind Verwaltungsleistungen für (i) OGAWs iSd. § 1 Abs. 2 KAGB, (ii) mit diesen vergleichbaren alternativen Investmentfonds iSd. § 1 Abs. 3 KAGB und (iii) Wagniskapitalfonds umsatzsteuerbefreit (§ 4 Nr. 8 Bst. h) UStG).
    • Für alternative Investmentfonds iSd § 1 Abs. 3 KAGB (AIFs) bedeutet dies derzeit aufgrund der restriktiven Auslegung eines vergleichbaren alternativen Investmentfonds durch die Finanzverwaltung (vgl. 4.8.13 Abs. 8 UStAE), dass Verwaltungsleistungen des AIFM an einen AIF grundsätzlich umsatzsteuerpflichtig sind.
    • AIFs sind aufgrund der passiven Vermögensanlage typischerweise keine Unternehmer iSd. Umsatzsteuerrechts, sodass die Umsatzsteuer auf Verwaltungsleistungen vom AIF nicht als Vorsteuer abziehbar ist, mithin zu definitiven Kosten auf Fondsebene führt. Diese belasten entweder die Investoren oder das Fondsmanagement.
    • Der Kostenaspekt wurde vielfach als Nachteil des Fondsstandortes Deutschlands benannt. In den europäischen Nachbarländern, insb. in Luxemburg, sind Verwaltungsleistungen an AIFs grundsätzlich umsatzsteuerfrei.
    • Die Erweiterung der Umsatzsteuerfreiheit durch das Fondsstandortgesetz (BGBl. 2021 I, 1498) in Bezug auf Wagniskapitalfonds wurde als Schritt in die richtige Richtung wahrgenommen. Damit verbunden waren jedoch Abgrenzungsschwierigkeiten, die in der praktischen Anwendung zu Rechtsunsicherheit führen.

    NEUE UMSATZSTEUERBEFREIUNG FÜR ALTERNATIVE INVESTMENTFONDS

    • Im Rahmen des Zukunftsfinanzierungsgesetzes (BGBl. I 2023, Nr. 354) wird nun die Umsatzsteuerfreiheit für Verwaltungsleistungen an AIFs eingeführt. Die Kategorie des „einem OGAW vergleichenbaren“ alternativen Investmentfonds sowie des Wagniskapitalfonds wird abgeschafft und eine generelle Umsatzsteuerfreiheit in Bezug auf AIFs eingeführt. Mit der Neuregelung wird die Herstellung von Wettbewerbsgleichheit mit anderen anderen europäischen Jurisdiktionen angestrebt (s. BT-Drs. 20/8292, S. 133).
    • Die Regelung ist zwingend, es ist kein Verzicht auf die Umsatzsteuerfreiheit vorgesehen.
    • In zeitlicher Hinsicht gilt die Neuregelung ab 1. Januar 2024.

    AUSWIRKUNGEN IN DER PRAXIS – DIE STEUERLICHE PERSPEKTIVE

    • Zukünftig bezieht auch ein AIF relevante Verwaltungsleistungen durch den AIFM als umsatzsteuerfreie Eingangsumsätze. Auf einen Vorsteuerabzug kommt es auf Fondsebene damit nicht mehr an.
    • Auf Ebene des AIFM sollte es durch die Neuregelung zu einem Anstieg der umsatzsteuerfreien Ausgangsumsätze kommen. Erbrachte Leistungen an einen AIF sind dahingehend zu prüfen, ob sie unter die Umsatzsteuerbefreiung fallen. Die Erhöhung von umsatzsteuerfreien Ausgangsumsätzen ist relevant für die Berechtigung des AIFM zum Vorsteuerabzug. Den Verwaltungsleistungen unmittelbar zuzuordnende Eingangsleistungen sind vollständig vom Vorsteuerabzug ausgeschlossen. Für Allgemeinkosten wird der Vorsteuerabzug nur entsprechend des individuellen Vorsteuerschlüssels gewährt (Anteil der USt-pflichtigen Ausgangsleistungen an den gesamten Ausgangsleistungen).
    • Die Umsatzsteuerbefreiung gilt unter bestimmten Voraussetzungen auch für Verwaltungsleistungen, die mittelbar an einen AIF gerichtet werden, z.B. bei bestimmten Leistungen eines Anlageberaters im Auslagerungsfall, der Beratungsleistungen für einen AIF an dessen AIFM erbringt.
    • Im Fall von Beratungsleistungen für einen ausländischen Fonds an dessen ausländischen AIFM (bspw. Luxemburger Fondsstruktur) gelten dieselben Grundsätze. Zwar wird die sonstige Leistung an einen Unternehmer aufgrund des Leistungsorts im Ausland nicht der deutschen Umsatzsteuer unterliegen. Die Umsatzsteuerbefreiung auf die Verwaltungsleistungen führt beim hypothetischen Leistungsort im Inland jedoch zu einem (teilweisen) Ausschluss des Vorsteuerabzugs auf Ebene des inländischen Anlageberaters (§ 15 Abs. 2 Satz 1 Nr. 2 UStG).
    • Die erbrachten Ausgangsleistungen sowie die Auswirkungen auf den Vorsteuerschlüssel sollten aus der Sicht von AIFMs und Anlageberatern analysiert werden.
    • Auf Ebene des leistenden AIFM oder Anlageberaters ist auch die Abrechnung an die geänderte umsatzsteuerliche Behandlung anzupassen. Ein unrichtiger Steuerausweis (§ 14c Abs. 1 UStG) führt zu der Pflicht zur Abführung der unrichtig ausgewiesenen Umsatzsteuer; ein Vorsteuerabzug besteht hinsichtlich der unrichtig ausgewiesenen Umsatzsteuer nicht. Rechnungen sind auf den richtigen Ausweis von Umsatzsteuer ggf. anzupassen.

    DIE INVESTMENTFONDS-PERSPEKTIVE

    • Die Neuregelung gilt für regulierte AIFs iSd. § 1 Abs. 3 KAGB und unabhängig von der Asset-Klasse. Sie erstreckt sich auf relevante Verwaltungsleistungen bspw. Portfolioverwaltung, Risikomanagement; andere Tätigkeiten wie bspw. die Verwahrung sind nicht umfasst.
    • Der Wegfall der Umsatzsteuerbelastung führt zu einer Verringerung der Kosten auf Ebene des AIF, wodurch die Anlagerendite steigt. Individuelle Vergütungsabreden in Bezug auf die Umsatzsteuer sind zu überprüfen.
    • Als Gegenstück zur Kostenverringerung auf Fonds-Ebene kommt es auf Ebene des AIFM bzw. des Anlageberaters zu einer Verringerung des Vorsteuerabzuges, dh. zu einer definitiven Kostenbelastung durch nicht abziehbare Umsatzsteuer auf Eingangsumsätze (bspw. Beratungsleistungen; zu weiteren Zusatzkosten, siehe unten zur Immobilien Perspektive).
    • Bei bestehenden Strukturen sollte die Fondsdokumentation auf Anpassungsbedarf überprüft werden. In neu aufzulegenden Strukturen sollte kommerziell von Fondsinitiatoren und AIFMs bzw. Fonds-Beratern die veränderte Belastungswirkung der Umsatzsteuer berücksichtigt werden.

    DIE IMMOBILIEN-PERSPEKTIVE

    • Eine weitere Auswirkung ergibt sich bei angemieteten Büros des AIFMs bzw. des Anlageberaters, da für diese Mietverträge aus Vermietersicht ggf. die Berechtigung zur umsatzsteuerpflichtigen Vermietung entfällt, sog. Umsatzsteueroption. Für eine wirksame Umsatzsteueroption muss der Mieter grundsätzlich mindestens 95% seiner Umsätze umsatzsteuerpflichtig erbringen. Der Vermieter hat ein Interesse an der umsatzsteuerpflichtigen Vermietung, wenn laufende Vorsteuerberichtigungszeiträume in Bezug auf die Immobilie bestehen und bei Erhöhung der umsatzsteuerfreien Vermietung auf den Vermieter Vorsteuerberichtigungen oder eine anteilige Versagung des Abzugs laufender Vorsteuer zukommen können (sog. Vorsteuerschaden).
    • Der Wegfall der Umsatzsteueroption führt dazu, dass die Miete zukünftig ohne Umsatzsteuer geschuldet wird, also umsatzsteuerfrei erfolgt. Der Mieter kann jedoch – je nach Regelung im Mietvertrag – verpflichtet sein, dem Vermieter einen entstehenden Vorsteuerschaden zu ersetzen.
    • In der zur Abrechnung des Mietvertrages gestellten Rechnung (meist in Form einer Dauermietrechnung) ist der Umsatzsteuerausweis ggf. anzupassen, um eine Haftung für einen unrichtigen Steuerausweis zu vermeiden (§ 14c Abs. 1 UStG, s.o.).
    • Bestehende Mietverträge mit AIFMs und Anlageberatern sollten aus Mieter- und Vermieter-Sicht auf Relevanz, potentielle Informations- und Schadensersatzpflichten sowie Anpassungsmöglichkeiten überprüft werden.
    Authors

    Dr. Maximilian Meyer

    Counsel

    Frankfurt

    Dr. Florian Schiefer

    Partner

    Frankfurt

    Frank Müller

    Partner

    Frankfurt

    More insights

  • Private Investors and Digital Health Attracting OIG Attention: General Compliance Program Guidance to Watch

    Private Investors and Digital Health Attracting OIG Attention: General Compliance Program Guidance to Watch

    ARTICLE / CLIENT ALERT

    Private Investors and Digital Health Attracting OIG Attention: General Compliance Program Guidance to Watch

    December 18, 2023

    Read time: 9 min

    Key takeaways
    Overview

    On November 6, 2023, the US Department of Health and Human Services (HHS) Office of Inspector General (OIG) published the General Compliance Program Guidance (GCPG) as a revised reference guide for the healthcare compliance community and other healthcare stakeholders. As noted in our previous On the Subject, the GCPG is part of the ongoing OIG modernization initiative and, like previous compliance program guidance, is nonbinding, voluntary guidance. Nonetheless, OIG guidance has a significant influence on how compliance programs and efforts are designed and implemented.

    Importantly, the GCPG specifically references technology companies as “new entrants to the healthcare sector” and notes “[t]he growing prominence of private equity and other forms of private investment” in the sector. Digital health companies and digital health programs within larger institutions, and investors of all types, should take note—and take action.

    In depth

    WHAT IS THE GCPG?

    The GCPG is the first of what will be many updated compliance program guidance documents.

    Historically, OIG issued various guidance documents to specific industry participants, such as hospitals, nursing homes and drug manufacturers. These documents are now between 15 and 25 years old. Earlier this year, OIG announced a plan to update these documents, with the first being the GCPG.

    The GCPG is a general overview of compliance program issues that apply across the healthcare industry spectrum, such as the seven elements of a compliance program as well as a summary of the fraud and abuse laws and OIG resources. In the GCPG, OIG also describes the differences between how large and small organizations may structure their compliance programs and address attendant risks. OIG has said that industry-specific compliance program guidance documents are in the works, with guidance for managed care and nursing homes expected to be published in 2024.

    WHAT DOES THE GCPG SAY ABOUT PRIVATE INVESTORS AND DIGITAL HEALTH?

    Despite its modest title, the “Other Compliance Considerations” section at the end of the GCPG is where we find the new discussion that applies to the digital health sector and investors. The section covers several “generally applicable risk areas”:

    • Quality and Patient Safety
    • New Entrants in the Health Care Industry
    • Financial Incentives: Ownership and Payment – Follow the Money
    • Financial Arrangements Tracking

    While quality and patient safety have long been areas of interest to OIG (the cited reference for existing OIG guidance on this subject is nearly 20 years old), the inclusion of these topics in the compliance program is different and discussed in more depth in our On the Subject linked above.

    The remaining areas appear not to have warranted independent OIG guidance in the past. None of these three areas is a traditional core subject of a compliance program; rather, they appear to represent conditions that OIG believes could negatively impact compliance, and so, are factors organizations should specifically consider when developing and implementing a compliance program.

    OIG’s concern about new entrants in the industry will sound familiar to any healthcare professional:

    New entrants are often unfamiliar with the unique regulations and business constraints that apply in the health care industry, as well as the range of Federal and State government agencies that regulate health care and enforce fraud and abuse laws.  Simply put, business practices that are common in other sectors create compliance risk in health care, including potential criminal, civil, and administrative liability.

    Accordingly, OIG urges new entrants to educate themselves about the specific legal and regulatory requirements that pertain to healthcare organizations so that they can fully appreciate the importance of compliance programs and efforts and, of course, develop and implement effective compliance programs.

    OIG’s description of new entrants is not entirely surprising, and includes technology companies, new investors, organizations providing nontraditional services (such as social services) and healthcare organizations diversifying into unfamiliar sectors, such as “developing health care technology.” This last category is an important reminder that compliance concerns are not uniform across the healthcare sector and may need fresh eyes to ensure a fulsome analysis.

    OIG’s concern about financial incentives and investors raises more questions than it answers. In this section, OIG suggests that the financial incentives built into certain ownership structures could undermine compliance efforts:

    The growing prominence of private equity and other forms of private investment in health care raises concerns about the impact of ownership incentives (e.g., return on investment) on the delivery of high quality, efficient health care.  Health care entities, including their investors and governing bodies, should carefully scrutinize their operations and incentive structures to ensure compliance with Federal fraud and abuse laws and that they are delivering high quality, safe care for patients.  An understanding of the laws applicable to the health care industry and the role of an effective compliance program is particularly important for investors that provide management services or a significant amount of operational oversight for and control in a health care entity. (emphasis added)

    OIG’s discussion in the GCPG on ownership incentives and private investment as having “growing prominence” is somewhat curious. Private investment in healthcare is a longstanding feature of our country’s healthcare system. The expectation that there will be a return on investment to the owners of a healthcare organization is perhaps the central feature of private investment.

    OIG seems particularly concerned about management companies, which are commonplace where licensure restrictions require professional ownership of the organization providing the clinical delivery of care. While the specific reference to “private equity” implies that OIG is focused on a particular market segment, there is nothing in the language that would exclude venture-backed or other privately sponsored healthcare organizations from the scope of this guidance. Given this, the scope and implications of OIG’s concerns with private investment in healthcare remain amorphous. Are public companies free of additional scrutiny, or could certain incentive-based stock ownership plans of public companies be problematic as well? Does the increased scrutiny apply to operators that are also owners? Are there some forms of private investment that are more concerning to OIG than others? Is simply having an expectation of a return on investment worrisome to OIG, or are other factors needed to pose more risk?

    In addition, OIG recommends that private investors should play a role in compliance oversight.  This statement also raises questions, such as: Is the scope of involvement limited to the ownership incentives that may implicate compliance concerns, or is the oversight broader? Should different classes of investors be expected to take on more or less responsibility here? Some investors are passive and do not have involvement in the organization or governance rights that permit their involvement—are they excluded? It is possible that OIG is concerned with investors that have specific board representation or that have an active role in management because of the fiduciary duties and direct participation in governance or management that go along with those roles. The language can be read, however, to demonstrate a general expectation of compliance oversight by all investors.

    Perhaps reflective of the variety of ways that these areas for consideration could impact compliance efforts, OIG notes that this section of the GCPG will be subject to updates and additions “based on general compliance concerns identified through OIG work, by the enforcement community, as well as feedback received from industry stakeholders.” Accordingly, we may see further guidance in the future.

    CONCLUSION AND TAKEAWAYS

    While OIG’s discussion of new entrants and private investment is short, the implications could be far-reaching and signal the beginning of increased scrutiny by OIG of the healthcare marketplace and its private ownership foundation. OIG’s high-level view appears to be that there is something about the incentives built within private investment structures that could negatively impact compliance efforts. While this high-level view is useful, many questions remain about the impact of OIG’s view for the healthcare community.

    The strategies for healthcare organizations to mitigate their risks are the same now as they were in the past:

    • Take steps to ensure that their board members and executives are trained on the healthcare legal and regulatory landscape
    • Work to ensure that the organization has an effective compliance program and that the board exercises appropriate oversight of that program
    • Monitor further OIG pronouncements for further guidance in this area

    Compliance professionals should also look to enforcement actions to see how the enforcement agencies utilize these areas of consideration in their investigations and enforcement efforts. In this regard, we have seen more False Claims Act cases name private equity sponsors as defendants and allege that the sponsor had a role in the alleged misconduct, or that the sponsor knew about the alleged misconduct and permitted it to continue. We expect this trend to continue and perhaps accelerate to include other investors or management entities in response to OIG’s statements in the GCPG.

    Similarly, private investors should note that OIG’s statements in the GCPG are consistent with recent action taken by CMS as it pertains to reporting of ownership and control data on the CMS 855A enrollment form, which we discussed in a previous On the Subject. On November 17, 2023, the US Department of Health and Human Services published a final rule requiring nursing facilities participating in Medicaid and skilled nursing facilities participating in Medicare to disclose detailed ownership, managerial, governance and personnel qualifications, with a particular focus on private equity and real estate investment trust (REIT) ownership. In a press release accompanying the final rule, CMS cited research suggesting that private equity ownership is associated with poorer staffing conditions at nursing facilities and resultant decreases in quality of care. CMS subsequently expanded the detailed disclosure requirements to other providers who are required to maintain an 855A enrollment record in order to receive reimbursement from Medicare. The reported data will be made public in an effort to increase transparency and provide consumers with more data to evaluate facilities and make informed choices about where to obtain care. It has yet to be determined whether enrolled providers and suppliers who disclose private equity and/or REIT ownership will be subject to enhanced scrutiny, including increased audit risk.

    Finally, organizations (including trade associations) should take advantage of OIG’s invitation to provide feedback to OIG.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Monica Wallace

    Partner

    Chicago

    More insights

  • Corporate Transparency Act: What to Know

    Corporate Transparency Act: What to Know

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act: What to Know

    December 18, 2023

    Read time: 5 min

    Key takeaways
    Overview

    The Corporate Transparency Act (CTA) introduces beneficial ownership reporting requirements effective January 1, 2024, for new and existing companies. Below is an overview of the new reporting obligations imposed by the CTA.

    In depth

    WHO REPORTS?

    Unless an exemption applies (see below), any corporation, limited liability company (LLC), limited partnership (LP) or other entity formed or registered to do business by filing a document with a US state or territory or an Indian tribe will be a “reporting company.”

    WHO IS EXEMPT?

    There are 23 exemptions from the CTA reporting requirement. These include, among others, public companies, broker-dealers, Securities Exchange Act-registered entities, investment advisers, insurance companies, pooled investment vehicles, tax exempt entities, large operating companies, certain wholly owned subsidiaries and inactive entities.

    WHAT GETS REPORTED?

    • Reporting Company: Name, “doing business as” name, business address, jurisdiction and tax identification number.
    • Beneficial Owners: Name, date of birth, residential address and photo ID.
    • Company Applicants (only for reporting companies formed or registered on or after January 1, 2024): Name, date of birth, business or residential address, and photo ID.

    WHO IS A BENEFICIAL OWNER?

    • Control Persons: An individual who, directly or indirectly, exercises substantial control over the reporting company (can be more than one):
      • Includes senior officers (e.g., president, chief executive officer, chief operating officer, chief financial officer, general counsel).
      • Captures anyone who is able to make important decisions on behalf of the reporting company, including the power to appoint and remove senior officers or a majority of the board of directors (or similar governing body).
    • 25% Owners: An individual who, directly or indirectly, owns or controls at least 25% of the ownership interests of the reporting company.
      • Ownership interests include equity (stock, LLC/LP interests, etc.), instruments convertible into equity, profits interests, options, etc.

    WHO IS A COMPANY APPLICANT?

    The individual who directly files the document that forms or registers the reporting company and the individual who is primarily responsible for directing or controlling such filing if more than one individual is involved in the filing. No more than two company applicants per company.

    WHAT ARE THE REPORTING DEADLINES?

    • Existing Reporting Companies (formed or registered before January 1, 2024): Initial report due by January 1, 2025.
    • New Reporting Companies (formed or registered on or after January 1, 2024): Initial report due within 90 days of formation or registration, but companies formed or registered after January 1, 2025, will need to file an initial report within 30 days of formation or registration.
    • Updates and Corrections: Changes to reported information must be reported within 30 days of the change.  No updates for changes to company applicant information.

    HOW TO REPORT?

    • Reports can be filed through the portal maintained by the US Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN). See www.fincen.gov/boi.
    • The cloud-based system will meet the highest Federal Information Security Management Act level.

    WHO GETS ACCESS TO THE FinCEN DATABASE?

    • Federal agencies engaged in law enforcement, national security or intelligence activity to advance such activity.
    • State, local and tribal law enforcement for use in criminal or civil investigations and with authorization from a court of competent jurisdiction.
    • Certain foreign agencies engaged in law enforcement, national security or intelligence activity.
    • Financial institutions subject to customer due diligence requirements, solely with the consent of the reporting company, to facilitate compliance with such requirements, and their regulators.
    • Certain Treasury officers and employees, including for tax administration.

    WHAT HAPPENS IF I DON’T REPORT? WHAT IF MY INFORMATION IS MISUSED?

    • There are civil and criminal penalties for willful reporting violations.
    • There are also civil and criminal penalties for unauthorized disclosure and use of information.

    WHAT IS A FinCEN IDENTIFIER?

    • An individual may submit the required information directly to FinCEN and receive a unique FinCEN identifier, which the individual may provide to a reporting company in lieu of the required personal information.
    • Reporting companies can also obtain a FinCEN identifier.

    WHERE DO I BEGIN?

    • Educate your company’s decisionmakers and leadership team.
    • Make the necessary changes and updates to your company’s org chart.
    • Identify potential beneficial owners.

    HOW CAN McDERMOTT HELP?

    • Assess your company’s reporting obligations, eligibility for exemptions and compliance requirements.
    • Assist foreign and domestic entities with issue-spotting.
    • Provide education and training for legal and compliance teams.

    Should you have any questions, please contact the authors of this article or your regular McDermott lawyer.

    Authors

    Nathan E. Barnett

    Partner

    Wilmington

    Daniel J. Bell

    Partner

    Washington, DC

    Sebastian Orozco Segrera

    Partner

    Washington, DC, Miami

    More insights